 |
SV Life Sciences Fund IISVLSF II closed in 1999 with total commitments of $280 million (plus $30 million of co-investments committed by partners and individuals affiliated with SVLS). As at 31 March 2010, the fund had invested $328 million (including re-investment) in 36 portfolio companies. To go to individual portfolio companies websites please click on company logo. Biotechnology / Biopharmaceuticals
Achillion: US
First investment: 2000 - Start Up Achillion is based in New Haven, CT, Achillion is focused on the discovery, development and commercialization of innovative small molecule therapeutics for the treatment and/or prevention of serious infections associated with drug resistant viruses or bacteria. 
Aderis Pharmaceuticals: US - Exited
First investment: 2001 - Expansion Aderis Pharmaceuticals was a Cardiovascular, renal and neurological disease focused therapeutics focused upon making a significant difference to people living with cardiovascular, renal and neurological diseases. 
Affibody: Sweden - Exited
First investment: 2001 - Early Stage Affibody is a biotech company that uses unique affinity ligands to develop products for molecular imaging, targeted therapy and biotechnology applications. The lead product is a Her2 affibody for clinical imaging in breast cancer, and its pipeline includes other oncology imaging affibodies. In addition, affibodies are sold as research reagents and for use in protein separations. 
Auxilium Pharmaceuticals: US - Exited
First investment: 2001 - Early Stage Auxilium developed a male hormone replacement therapy. 
Celldex/Lorantis: UK - Exited
First investment SVLSF II: 2000 - Start Up First investment SVLSF III: 2003 - Early Stage Celldex merged with the quoted company Avant Immunotherapeutics (ticker:'AVAN') in March 2008. Celldex, formerly a wholly owned subsidiary of Medarex Inc., merged with Lorantis Ltd in 2005. Celldex pursues immunological approaches to the treatment of cancers, infectious disease and immunological disorders. 
Cellzome: Germany
First investment: 2001 - Start Up Cellzome is a drug discovery company building a R&D pipeline in chronic diseases by leveraging its unique drug proteomics engine. The business is based in Heidelberg, Germany and Cambridge, UK. 
Cognis: Luxembourg
First investment: 2001 - Buyout Cognis is a global supplier of specialty chemicals using renewable, bio-degradable,natural oils as the key raw material base. Customers include international manufacturers of cosmetics, vitamins and nutritional supplements and homecare products as well as a broad range of industrial customers. 
Eyetech Pharmaceuticals: US - Exited
First investment: 2000 - Early Stage Eyetech was bought by OSI Pharmaceuticals after our exit. Opthalmolological drug development. 
Ingenium: Germany - Exited
First investment: 2000 - Early Stage Ingenium was a functional genomics and drug development company. 
KuDOS Pharmaceuticals: UK - Exited
First investment: 1999 - Start Up KuDOS was an oncology drug development company. 
Metris Therapeutics: UK - Exited
First investment SVLSF I: 1998 - Start Up First investment SVLSF II: 2000 - Start Up Metris is a women’s healthcare company that is developing drugs for the treatment of chronic gynecological and menstrual conditions. 
Orchid Chemicals and Pharmaceuticals: India - Exited
Private investment in Public Equity First investment: 1999 - Expansion Orchid manufactured bulk generic pharmaceuticals. 
Oxagen: UK
First investment: 2000 - Expansion Oxagen, based in Oxford, UK, is a biopharmaceutical company building a novel drug pipeline based on targets validated in man through its genetic platform. Oxagen’s work is focused in inflammatory and metabolic diseases. 
Quantum Dot: US - Exited
First investment: 2000 - Early Stage Quantum Dot developed nanocrystal biological reagents. 
Solexa: UK - Exited
First investment: 2001 - Start Up Solexa used ultra high throughput DNA sequencing. 
Third Wave Technologies: US - Exited
First investment: 1999 - Expansion Third Wave developed products for analysing genetic variations. 
Trine Pharmaceuticals: US - Exited
First investment: 2001 - Expansion Trine, formerly Essential Therapeutics Inc., in-licenses, develops and plans to commercialize new classes of pharmaceutical products focused on renal, metabolic and GI clinical areas. 
Versicor: US - Exited
First investment: 1999 - Expansion Versicor was a drug development company for infectious diseases (Changed name to Vicurion Pharmaceuticals in 2003) 
| |
